Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Amy Levin is ONCY's VP Clinical Operations & NOT on the BOD

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Mar 11, 2023 5:46pm

167 Views

Post# 35332923

RE:RE:RE:RE:RE:RE:RE:RE:RE:Amy Levin is ONCY's VP Clinical Operations & NOT on the BOD

Noteable,

Thanks for this remarkably detailed and insightful post. I remain hopeful. You are right, more options are can potentially be good, but they lead to more complexity. That may mean more time.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta